Current Report Filing (8-k)
0000906709 false 0000906709 2021-01-11
2021-01-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
to Section 13 or 15(d) of the Securities Exchange Act of
report (Date of earliest event reported):
January 11, 2021
Name of Registrant as Specified in Charter)
455 Mission Bay Boulevard South
of Principal Executive Offices and Zip Code)
telephone number, including area code:
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
pursuant to Section 12(b) of the Act:
each exchange on which
Common Stock, $0.0001 par value
NASDAQ Global Select Market
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
growth company ☐
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Results of Operations and Financial Condition.
see the disclosure relating to the estimated cash and investments
in marketable securities of Nektar Therapeutics, a Delaware
corporation (the “Company”), set forth under Item 7.01 “Regulation
FD Disclosure” of this Current Report on Form 8-K, which is
incorporated by reference into this Item 2.02.
7.01 Regulation FD Disclosure.
January 6, 2021, the Company announced that President and Chief
Executive Officer, Howard Robin, will make a presentation at the
upcoming 39th Annual J.P. Morgan Virtual Healthcare
Conference on Monday, January 11, 2021, at 11:50 a.m. Pacific Time.
The presentation and Q&A session will be accessible via Webcast
through a link posted on the Investor Events Calendar section of
the Nektar website:
https://ir.nektar.com/events-and-presentations/events. This Webcast
will be available for replay until February 10, 2021.
Mr. Robin intends to announce that, based upon the Company’s
preliminary estimates, as of December 31, 2020, the Company had
cash and investments of approximately $1.2 billion. This financial
information has been prepared by and is the responsibility of the
Company’s management and has not been audited by the Company’s
independent registered public accounting firm. Accordingly, the
Company’s independent registered public accounting firm does not
express an opinion on or provide any other form of assurance with
respect to this preliminary data. This financial information is
subject to the completion of the Company’s year-end financial
closing procedures, the preparation of the Company’s consolidated
financial statements, and the completion of the audit of the
Company’s consolidated financial statements as of and for the year
ended December 31, 2020, and the Company’s actual results may
differ from these estimates.
expects the presentation and Q&A session will include certain
forward-looking statements regarding the Company’s business and
proprietary drug candidates, the timing of the start and conclusion
of planned or ongoing clinical trials, the timing and outcome of
regulatory decisions, and future availability of clinical trial
data. Actual results could differ materially from these
forward-looking statements, which are subject to important risks
and uncertainties set forth in the Company’s Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission on
November 6, 2020. The Company undertakes no obligation to update
forward-looking statements, whether as a result of new information,
future events or otherwise.
The information in this Item 7.01 is being furnished and shall not
be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained in
this Item 7.01 shall not be incorporated by reference into any
filing with the Securities and Exchange Commission (the “SEC”) made
by Nektar, whether made before or after the date hereof, regardless
of any general incorporation language in such filing.
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
/s/ Mark A.
||General Counsel and
January 11, 2021